Want to join the conversation?
Ricky Goldwasser of Morgan Stanley asks about SG&A. $ESRX said there are no significant items that would drive SG&A across the organization. It will be mostly about managing costs and trends. Even outside SG&A, there are no significant items that would impact EBITDA in 2H16.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?